Saturday 17 October 2026
Export MESO’s income statement to Excel — free account
Mesoblast Limited
MESO Healthcare Biotechnology
Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.
13.28
0.67
−4.80%
Follow MESO
| Older periods | Jun '23 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | — | — | — |
| (16.40%) | 0.00% | 0.00% | 0.00% | ||
| (12.30%) | 0.00% | 0.00% | 0.00% | ||
ROIC |
(7.18%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(199.57%) | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
340.52 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.82) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(63.58) | (75.87) | (70.01) | (84.36) | |
Capital Expenditures |
(0.31) | (0.31) | (0.38) | (0.83) | |
| Other line items | |||||
Cash ROIC |
(9.32%) | (10.81%) | (11.32%) | (10.14%) | |
Accounts Receivable Turnover |
1.32 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
1.28 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
265.13 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
362.47% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
338.27% | — | — | — | |
Share Based Compensation of Revenue |
48.73% | — | 0.00% | 0.00% | |
Interest Coverage |
(1.55) | — | — | — | |
Operating CF/Net income |
0.77 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
3.03 | 0.00 | 5.06 | 4.63 | |
Capex/Depreciation |
(0.08) | 0.00 | (0.07) | (0.10) | |
Revenue per Share |
0.10 | — | — | — | |
Operating CF per Share |
(0.81) | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.00 | 0.00 | 0.00 |
Columns are period end dates